Lyra Therapeutics Inc
NASDAQ:LYRA
Intrinsic Value
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. [ Read More ]
The intrinsic value of one LYRA stock under the Base Case scenario is 1.61 USD. Compared to the current market price of 4.72 USD, Lyra Therapeutics Inc is Overvalued by 66%.
Valuation Backtest
Lyra Therapeutics Inc
Run backtest to discover the historical profit from buying and selling LYRA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Lyra Therapeutics Inc
Current Assets | 104.8m |
Cash & Short-Term Investments | 102.8m |
Other Current Assets | 2.1m |
Non-Current Assets | 37.8m |
PP&E | 35.3m |
Other Non-Current Assets | 2.5m |
Current Liabilities | 19.6m |
Accounts Payable | 3.1m |
Accrued Liabilities | 14.8m |
Other Current Liabilities | 1.7m |
Non-Current Liabilities | 33.6m |
Other Non-Current Liabilities | 33.6m |
Earnings Waterfall
Lyra Therapeutics Inc
Revenue
|
1.6m
USD
|
Operating Expenses
|
-67.1m
USD
|
Operating Income
|
-65.5m
USD
|
Other Expenses
|
2.8m
USD
|
Net Income
|
-62.7m
USD
|
Free Cash Flow Analysis
Lyra Therapeutics Inc
LYRA Profitability Score
Profitability Due Diligence
Lyra Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Lyra Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
LYRA Solvency Score
Solvency Due Diligence
Lyra Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Lyra Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LYRA Price Targets Summary
Lyra Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for LYRA is 12.24 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.
Ownership
LYRA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LYRA Price
Lyra Therapeutics Inc
Average Annual Return | -43.92% |
Standard Deviation of Annual Returns | 12.8% |
Max Drawdown | -89% |
Market Capitalization | 270.1m USD |
Shares Outstanding | 59 743 100 |
Percentage of Shares Shorted | 0.82% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-05-01. The firm is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.
Contact
IPO
Employees
Officers
The intrinsic value of one LYRA stock under the Base Case scenario is 1.61 USD.
Compared to the current market price of 4.72 USD, Lyra Therapeutics Inc is Overvalued by 66%.